US government funding yielded hundreds of patents for China-based researchers
Data shows U.S. government funding behind 1,020 patents for China-based inventors
Critics argue China unfairly benefits in fields like biotechnology and semiconductors
Data fans controversy around US-China science pact
Adds Chinese government comment in paragraphs 11, 12
By Michael Martina
WASHINGTON, Aug 29 (Reuters) -The U.S. Defense Department, NASA and other government agencies funded research that led to more than 1,000 U.S. patents for China-based inventors since 2010, including in sensitive fields such as biotechnology and semiconductors, data from the U.S. patent agency showed.
The U.S. patent data, which was reviewed by Reuters and has not been reported previously, will amplify calls to cancel or renegotiate the landmark U.S.-China Science and Technology Agreement, a cooperation deal that critics say disproportionately benefits Washington's top geopolitical rival.
The U.S. Patent and Trademark Office supplied the data this month to the House of Representatives' select committee on China. In June, it asked the agency whether U.S. funding resulted in Chinese breakthroughs, aiming to highlight what it views as the risks of renewing the pact.
According to the patent office, the agency granted 1,020 patents from 2010 through the first quarter of 2024 that were both funded at least in part by the U.S. government and involved at least one China-residing inventor. The data does not detail whether U.S. entities or individuals share the patents.
The patents included 197 in pharmaceuticals and 154 in biotechnology, both strategic industries for China and the United States.
Funding from various U.S. government agencies supported the research, leading to 92 patents through Pentagon funding, 175 from Department of Energy money and four from NASA financial support. The U.S. space agency faces prohibitions under U.S. law from cooperating with China or Chinese companies.
Funding from the Department of Health and Human Services yielded 356 such patents, the most of any agency.
"It's alarming that U.S. taxpayers have unwittingly funded over 1,000 patents claimed by Chinese entities, with the Department of Defense accounting for nearly 100 of these patents," the select committee's chairman, Republican Representative John Moolenaar, said in an email to Reuters.
The patent office, NASA and the departments of defense, energy and health did not respond to requests for comment.
The State Department, which is responsible for renegotiating the China agreement, said it remains in communication with China about the accord. "The United States remains committed to advancing and protecting U.S. interests in science and technology," a department spokesperson said.
Liu Pengyu, a spokesperson for China's embassy in Washington, said science and technology was an "open business."
"We hope that some officials in the U.S. will abandon the Cold War mentality," Liu said.
The data provided by the patent authority to the House committee in a letter dated Aug. 14 did not disclose specific projects or patents. There was no indication that the funding was the direct result of the agreement, which after its signing in 1979 laid the foundation for a boom in U.S.-China academic and commercial exchanges.
The patents covered advances in fields including semiconductors, molecular chemistry and polymers, chemical engineering, nanotechnology and medical technology.
Such patents dropped from an annual high in 2019 of 99, to 61 in 2023. In 2024, 16 were recorded in the first quarter despite heightened U.S. government concern that Chinese science and technology advances present a national security threat.
POSSIBLE EXTENSION OF CHINA PACT
Once hailed as a stabilizing force in U.S.-China relations, the cooperation agreement has come under fire from lawmakers concerned about Beijing's growing military power and alleged theft of U.S. intellectual property.
Proponents of renewing the deal argue that ending it would stifle academic and commercial cooperation and prevent the U.S. from learning about China's technical advances.
A second six-month extension to the agreement, which expired in August 2023, ended on Tuesday. Another short-term extension could occur in the coming days as both sides have sought to renegotiate its terms.
The patents identified by the U.S. patent office represent a small fraction of China's global patents. Patents grant exclusive legal rights to inventors but also publicly disclose technical information about those inventions.
In one measure of global innovation, China has in recent years surpassed the U.S. to become the world's leading filer of patent applications.
Reporting by Michael Martina; Editing by Don Durfee and Cynthia Osterman
면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.
온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.
이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.